U.S. markets open in 2 hours 54 minutes
  • S&P Futures

    3,314.00
    +14.75 (+0.45%)
     
  • Dow Futures

    27,334.00
    +191.00 (+0.70%)
     
  • Nasdaq Futures

    11,187.25
    +37.75 (+0.34%)
     
  • Russell 2000 Futures

    1,495.10
    +6.30 (+0.42%)
     
  • Crude Oil

    39.94
    +0.14 (+0.35%)
     
  • Gold

    1,892.70
    -14.90 (-0.78%)
     
  • Silver

    23.70
    -0.82 (-3.36%)
     
  • EUR/USD

    1.1715
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    0.6640
    0.0000 (0.00%)
     
  • Vix

    26.23
    -1.55 (-5.58%)
     
  • GBP/USD

    1.2734
    -0.0002 (-0.02%)
     
  • USD/JPY

    104.9960
    +0.0720 (+0.07%)
     
  • BTC-USD

    10,479.88
    -61.88 (-0.59%)
     
  • CMC Crypto 200

    222.01
    +8.26 (+3.86%)
     
  • FTSE 100

    5,961.96
    +132.50 (+2.27%)
     
  • Nikkei 225

    23,346.49
    -13.81 (-0.06%)
     

HOOKIPA Pharma to Present at SVB Leerink’s CybeRx Series Vaccine Forum

Hookipa Pharma Inc

NEW YORK and VIENNA, Austria, Sept. 16, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate and present at SVB Leerink’s CybeRx Series: Vaccine Forum, taking place September 23 – 24, 2020:

  • HOOKIPA Fireside Chat: Wednesday, September 23rd at 12:00 PM ET with Joern Aldag (CEO) and Igor Matushansky (CMO)

About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that reprograms the body’s immune system.

HOOKIPA’s proprietary arenavirus-based technologies, non-replicating (VaxWave®) and replicating (TheraT®), induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s “off-the-shelf” viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches.

HOOKIPA’s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections.

In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers. The Phase 1/2 clinical trial for HB-201 was initiated in December 2019. The HB-202 IND application was cleared by the FDA in June 2020.

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact:

Media

Investors

Nina Waibel

Matt Beck

Senior Director - Communications

Executive Director - Investor Relations

nina.waibel@hookipapharma.com

matthew.beck@hookipapharma.com